ALSO NOTED: Dusa, River's Edge settle patent claims; Abaxis appoints new operating VP;

> Dermatological drug maker Dusa Pharmaceuticals has settled a patent-infringement claim with River's Edge Pharmaceuticals, which has been selling a copycat form of Dusa's Nicomide acne med. Report

> Abaxis, which makes portable blood-analysis devices, has hired a new vice president of operations, Donald P. Wood. Report

> Indian regulators who've been cracking down on price-controlled drugs found that more than half the products it sampled were overpriced or had no government-approved pricing. Report

> After five years in partnership with Roche, Kosan Biosciences says it will seek a new partner for its experimental cancer therapy epothilone. Report

> Amid the upbeat tone to yesterday's release of third quarter income at Bristol-Myers Squibb, executives hit a sour note with their announcement that they would probably not seek FDA approval of their bladder drug vinflunine. Report

> With sales of Aranesp and Epogen on the decline, biotech giant Amgen is feeling the impact right where it hurts the most: The bottom line. Report

And Finally... The saga of drug-resistant staph continues--in Fido and Muffin. Vets say cases of MRSA infections in animals are on the rise, too. Report

Suggested Articles

Post-Tesaro buyout, don’t expect GlaxoSmithKline to spring for more commercial-stage oncology products anytime soon.

Already a fast-growing blockbuster, Novo Nordisk's injectable Ozempic won a major heart-helping FDA nod that could bode well for its oral sibling.

Bayer's new Vitrakvi for tumors with NTRK gene fusions is meeting skepticism in England and Germany, where cost watchdogs on Friday rejected it.